CNSX:MYM

17031 Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume266,726 shs
Average Volume399,857 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

17031 (CNSX:MYM) Vs. CHV, PREV, COM, CURE, HALO, and LTY

Should you be buying MYM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to 17031, including (CHV) (CHV), (PREV) (PREV), 138267 (COM.TO) (COM), Direxion Daily Healthcare Bull 3X Shares (CURE), Halozyme Therapeutics (HALO), and Liberty Biopharma (LTY).

17031 (CNSX:MYM) and (CHV) (CNSX:CHV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares 17031 and (CHV)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
17031N/AN/AN/AN/AN/A
(CHV)N/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for 17031 and (CHV), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
170310000N/A
(CHV)0000N/A

Profitability

This table compares 17031 and (CHV)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
17031N/AN/AN/A
(CHV)N/AN/AN/A

17031 (CNSX:MYM) and (PREV) (CNSX:PREV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares 17031 and (PREV)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
17031N/AN/AN/AN/AN/A
(PREV)N/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for 17031 and (PREV), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
170310000N/A
(PREV)0000N/A

Profitability

This table compares 17031 and (PREV)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
17031N/AN/AN/A
(PREV)N/AN/AN/A

17031 (CNSX:MYM) and 138267 (COM.TO) (TSE:COM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares 17031 and 138267 (COM.TO)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
17031N/AN/AN/AN/AN/A
138267 (COM.TO)N/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for 17031 and 138267 (COM.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
170310000N/A
138267 (COM.TO)0000N/A

Profitability

This table compares 17031 and 138267 (COM.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
17031N/AN/AN/A
138267 (COM.TO)N/AN/AN/A

17031 (CNSX:MYM) and Direxion Daily Healthcare Bull 3X Shares (CNSX:CURE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Profitability

This table compares 17031 and Direxion Daily Healthcare Bull 3X Shares' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
17031N/AN/AN/A
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/A

Valuation and Earnings

This table compares 17031 and Direxion Daily Healthcare Bull 3X Shares' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
17031N/AN/AN/AN/AN/A
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for 17031 and Direxion Daily Healthcare Bull 3X Shares, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
170310000N/A
Direxion Daily Healthcare Bull 3X Shares0000N/A

Halozyme Therapeutics (NEO:HALO) and 17031 (CNSX:MYM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Halozyme Therapeutics and 17031's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme TherapeuticsN/AN/AN/A
17031N/AN/AN/A

Earnings and Valuation

This table compares Halozyme Therapeutics and 17031's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme TherapeuticsC$267.59 million0.00C$130.40 millionC$0.91N/A
17031N/AN/AN/AN/AN/A

Halozyme Therapeutics has higher revenue and earnings than 17031.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Halozyme Therapeutics and 17031, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics00014.00
170310000N/A

Halozyme Therapeutics currently has a consensus target price of C$0.27, indicating a potential upside of ∞.

Summary

Halozyme Therapeutics beats 17031 on 2 of the 2 factors compared between the two stocks.

Liberty Biopharma (CVE:LTY) and 17031 (CNSX:MYM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Liberty Biopharma and 17031's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Liberty BiopharmaN/AN/AN/A
17031N/AN/AN/A

Earnings and Valuation

This table compares Liberty Biopharma and 17031's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liberty BiopharmaN/AN/AN/AC($0.16)-12.66
17031N/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Liberty Biopharma and 17031, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Liberty Biopharma0000N/A
170310000N/A


17031 Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.00
LTY
Liberty Biopharma
0.6$2.00flatC$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49flatC$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32flatC$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.